Compare Abeona Therapeutics Inc (ABEO) vs Blackrock Inc (BLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Blackrock Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Blackrock Inc trades at $985.97 (market cap $156.46B). The key difference: Blackrock Inc is far larger — about 419.1× Abeona Therapeutics Inc's market cap, and Blackrock Inc pays a 2.27% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BLK | |
|---|---|---|
Market Cap | $373.32M | $156.46B |
Sector | Health | Financials |
52-Week High | $7.23 | $1.20K |
52-Week Low | $4.17 | $922.90 |
Enterprise Value | $228.22M | $158.28B |
Volume | — | 641,547 |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BlackRock (BLK) trades at $1,009.43, up 1.38% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $12.53 exceeding expectations. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights expansion into Nasdaq-100 ETFs and Bitcoin ETF offerings, positioning for growth in private markets and AI-driven demand.
Outlook remains positive with a consensus price target of $1,260, reflecting 25% upside. Key risks include volatile cash flows and competitive pressures in ETF markets. Institutional sentiment is strongly bullish, with 76% of analysts rating Buy. Earnings on July 15 will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
